Novel TYK2 Inhibitors with an N-(Methyl-d3)pyridazine-3-carboxamide Skeleton for the Treatment of Autoimmune Diseases-Reference-Cited by-同舟云学术

Novel TYK2 Inhibitors with an N-(Methyl-d₃)pyridazine-3-carboxamide Skeleton for the Treatment of Autoimmune Diseases

Published:2022-10-06 Issue:11 Volume:13 Page:1730-1738
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Liu Fei¹²,Wang Bin²,Liu Yanlong²,Shi Wei²,Tang Xujing²,Wang Xiaojin²,Hu Zhongyuan²,Zhang Ying²,Guo Yahui²,Chang Xiayun²,He Xiangyi²,Xu Hongjiang²,He Ying¹^ORCID

Affiliation:

1. School of Chemistry and Chemical Engineering, Nanjing University of Science and Technology, Nanjing 210094, China

2. R&D Institute, Chia Tai Tianqing Pharmaceutical Group Co., Ltd, 1099 Fuying Road, Jiangning District, Nanjing 211122, China

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.2c00334

Reference42 articles.

1. Cytokine receptor signaling through the Jak–Stat–Socs pathway in disease

2. JAK inhibitors in autoinflammation

3. The JAK/STAT signaling pathway: from bench to clinic

4. Targeting JAK/STAT signaling pathways in treatment of inflammatory bowel disease

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inverse kinetic isotope effect in singlet-to-triplet intersystem crossing contributes to greater robustness of deuterated organocatalyst;Bulletin of the Chemical Society of Japan;2024-03-07

2. Identification of Whole-Blood DNA Methylation Signatures and Rules Associated with COVID-19 Severity;Frontiers in Bioscience-Landmark;2023-11-08

3. Progress on the Pharmacological Targeting of Janus Pseudokinases;Journal of Medicinal Chemistry;2023-08-14

4. Impact of Catalyst Deuteration on the Reactivity of Chiral Phase‐Transfer Organocatalysts;Chemistry – A European Journal;2023-07-28

5. Design, synthesis and biological evaluation of novel N-(methyl-d) pyridazine-3-carboxamide derivatives as TYK2 inhibitors;Bioorganic & Medicinal Chemistry Letters;2023-04